Matthew D. Mitchell and Anna Parsons write on regulatory hurdles faced in introducing a new cancer drug, despite the drug already having been approved by the FDA.
Read it at the Wall Street Journal [2].
Links[1] https://www.mercatus.org/external-people/anna-miller-parsons [2] https://www.wsj.com/articles/regulators-wonder-if-cancer-patients-need-new-treatments-11572475291
Regulators Wonder if Cancer Patients ‘Need’ New Treatments
Anna Miller (Parsons) [1]
Matthew D. Mitchell and Anna Parsons write on regulatory hurdles faced in introducing a new cancer drug, despite the drug already having been approved by the FDA.
Read it at the Wall Street Journal [2].